Apart from the improved intestinal permeability, researchers have also found reduced colonic inflammation (e.g., IL-6, IL-1β, TNF-α) and overall disease activity index (DAI) after urolithin A therapy which active the AHR in 2, 4, 6trinitrobenzenesulphonic acid (TNBS)-induced colitis models (Singh et al., 2019). The gene discussed is AHR; the disease is colitis.